temozolomide has been researched along with Cancer of Kidney in 13 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Temozolomide is a rapidly absorbed chemotherapeutic agent, achieving significant central nervous system penetration." | 6.72 | Alternating chemo-immunotherapy with temozolomide and low-dose interleukin-2 in patients with metastatic melanoma. ( Hansson, J; Månsson-Brahme, E; Masucci, GV; Nilsson, B; Ragnarsson-Olding, B; Wagenius, G, 2006) |
| "In heavily pretreated patients with refractory/relapsed solid tumors, the vincristine, irinotecan, and temozolomide regimen seemed promising in Ewing sarcoma patients and was well tolerated." | 3.91 | Vincristine, irinotecan, and temozolomide treatment for refractory/relapsed pediatric solid tumors: A single center experience. ( Büyükkapu Bay, S; Çakır, FB; Darendeliler, E; Görgün, O; Kebudi, R; Zülfikar, B, 2019) |
| "Temozolomide is a rapidly absorbed chemotherapeutic agent, achieving significant central nervous system penetration." | 2.72 | Alternating chemo-immunotherapy with temozolomide and low-dose interleukin-2 in patients with metastatic melanoma. ( Hansson, J; Månsson-Brahme, E; Masucci, GV; Nilsson, B; Ragnarsson-Olding, B; Wagenius, G, 2006) |
| "Temozolomide was initially studied intravenously at doses between 50-200 mg m-2 and subsequently was given orally up to 1,200 mg m-2." | 2.67 | Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). ( Blackledge, GR; Brampton, MH; Hoffman, R; Newlands, ES; Quarterman, CP; Rustin, GJ; Slack, JA; Smith, DB; Stevens, MF; Stuart, NS, 1992) |
| "Brain metastases from renal cell carcinoma (RCC) cause significant morbidity and mortality." | 2.43 | Radiation therapy in the management of brain metastases from renal cell carcinoma. ( Amato, R; Doh, LS; Paulino, AC; Teh, BS, 2006) |
| "First clinical reports on treating brain metastases with temozolomide describe varying effects." | 1.35 | Homogeneous MGMT immunoreactivity correlates with an unmethylated MGMT promoter status in brain metastases of various solid tumors. ( Heppner, FL; Ingold, B; Moch, H; Schraml, P, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (7.69) | 18.2507 |
| 2000's | 8 (61.54) | 29.6817 |
| 2010's | 3 (23.08) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Navale, P | 1 |
| Chatterjee, D | 1 |
| Itani, M | 1 |
| Trikalinos, NA | 1 |
| Büyükkapu Bay, S | 1 |
| Kebudi, R | 1 |
| Görgün, O | 1 |
| Zülfikar, B | 1 |
| Darendeliler, E | 1 |
| Çakır, FB | 1 |
| Venkatramani, R | 1 |
| Malogolowkin, MH | 1 |
| Mascarenhas, L | 1 |
| Polley, MY | 1 |
| Freidlin, B | 1 |
| Korn, EL | 1 |
| Conley, BA | 1 |
| Abrams, JS | 1 |
| McShane, LM | 1 |
| Ingold, B | 1 |
| Schraml, P | 1 |
| Heppner, FL | 1 |
| Moch, H | 1 |
| Park, DK | 1 |
| Ryan, CW | 1 |
| Dolan, ME | 1 |
| Vogelzang, NJ | 1 |
| Stadler, WM | 1 |
| Sunkara, U | 1 |
| Walczak, JR | 1 |
| Summerson, L | 1 |
| Rogers, T | 1 |
| Eisenberger, M | 1 |
| Denmeade, S | 1 |
| Pili, R | 1 |
| Huff, CA | 1 |
| Sinibaldi, V | 1 |
| Carducci, MA | 1 |
| Bex, A | 1 |
| Kerst, J | 1 |
| Mallo, H | 1 |
| Van Tinteren, H | 1 |
| Horenblas, S | 1 |
| De Gast, GC | 1 |
| Moreno Antón, F | 1 |
| Casado Herraez, A | 1 |
| Puente Vázquez, J | 1 |
| Gómez Díaz, R | 1 |
| Aragoncillo, P | 1 |
| Díaz-Rubio García, E | 1 |
| Doh, LS | 1 |
| Amato, R | 1 |
| Paulino, AC | 1 |
| Teh, BS | 1 |
| Masucci, GV | 1 |
| Månsson-Brahme, E | 1 |
| Ragnarsson-Olding, B | 1 |
| Nilsson, B | 1 |
| Wagenius, G | 1 |
| Hansson, J | 1 |
| Sinkovics, J | 1 |
| Newlands, ES | 1 |
| Blackledge, GR | 1 |
| Slack, JA | 1 |
| Rustin, GJ | 1 |
| Smith, DB | 1 |
| Stuart, NS | 1 |
| Quarterman, CP | 1 |
| Hoffman, R | 1 |
| Stevens, MF | 1 |
| Brampton, MH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Study of Gamma Knife Radiosurgery and Temozolomide (Temodar) for Newly Diagnosed Brain Metastases[NCT00582075] | Phase 2 | 25 participants (Actual) | Interventional | 2002-07-31 | Completed | ||
| A Pilot Study Investigating Neoadjuvant Temozolomide-based Proton Chemoradiotherapy for High-Risk Soft Tissue Sarcomas[NCT00881595] | Phase 2 | 0 participants (Actual) | Interventional | 2009-02-28 | Withdrawn (stopped due to No patients accrued since study opened) | ||
| Phase 1b Trial of 5-fluorouracil, Leucovorin, Irinotecan in Combination With Temozolomide (FLIRT) and Bevacizumab for the First-line Treatment of Patients With MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer.[NCT04689347] | Phase 1 | 18 participants (Anticipated) | Interventional | 2021-01-01 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00582075)
Timeframe: 2 years
| Intervention | weeks (Median) |
|---|---|
| Radiosurgery 15-24 Gy + Adjuvant Temozolomide | 31 |
Patients developing distant brain failure (DBF) at one year. An approximation method was used to arrive at the reported percentage. (NCT00582075)
Timeframe: 1 years
| Intervention | percentage of participants (Number) |
|---|---|
| Radiosurgery 15-24 Gy + Adjuvant Temozolomide | 37 |
1 review available for temozolomide and Cancer of Kidney
| Article | Year |
|---|---|
Radiation therapy in the management of brain metastases from renal cell carcinoma.
Topics: Brain Neoplasms; Carcinoma, Renal Cell; Dacarbazine; Humans; Kidney Neoplasms; Metalloporphyrins; Ne | 2006 |
5 trials available for temozolomide and Cancer of Kidney
| Article | Year |
|---|---|
A phase II trial of oral temozolomide in patients with metastatic renal cell cancer.
Topics: Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Carcinoma, Renal Cell; Dacarbazine; Drug | 2002 |
A phase II trial of temozolomide and IFN-alpha in patients with advanced renal cell carcinoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto | 2004 |
Extended continuous oral temozolomide in patients with progressive metastatic renal cell carcinoma not responding to interferon alpha 2b.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Combined Modality T | 2005 |
Alternating chemo-immunotherapy with temozolomide and low-dose interleukin-2 in patients with metastatic melanoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Fema | 2006 |
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar | 1992 |
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar | 1992 |
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar | 1992 |
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar | 1992 |
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar | 1992 |
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar | 1992 |
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar | 1992 |
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar | 1992 |
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar | 1992 |
7 other studies available for temozolomide and Cancer of Kidney
| Article | Year |
|---|---|
Tuberous sclerosis complex mutations in patients with pancreatic neuroendocrine tumors. Observations on phenotypic and treatment-related associations.
Topics: Adult; Aged; Capecitabine; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Mutation; Neuroendoc | 2023 |
Vincristine, irinotecan, and temozolomide treatment for refractory/relapsed pediatric solid tumors: A single center experience.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool; | 2019 |
Treatment of multiply relapsed wilms tumor with vincristine, irinotecan, temozolomide and bevacizumab.
Topics: Adolescent; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevac | 2014 |
Statistical and practical considerations for clinical evaluation of predictive biomarkers.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Dac | 2013 |
Homogeneous MGMT immunoreactivity correlates with an unmethylated MGMT promoter status in brain metastases of various solid tumors.
Topics: Alkylating Agents; Brain Neoplasms; Breast Neoplasms; Dacarbazine; DNA Methylation; DNA Modification | 2009 |
Cardiac metastasis from uterine leiomyosarcoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dacarbazine; Deoxycytidin | 2006 |
[The effect of oxygenation on the biological behaviour of tumours].
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherap | 2007 |